Search Results - "Wu, Jinzi J."

Human Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ASC42, a Novel Farnesoid X Receptor Agonist by He, Handan, Wu, Jinzi J.

“…Background ASC42 is a non-steroidal farnesoid X receptor agonist currently in clinical development for chronic liver diseases, such as nonalcoholic fatty liver…”
Get full text

Long-term positive severe acute respiratory syndrome coronavirus 2 ribonucleic acid and therapeutic effect of antivirals in patients with coronavirus disease: Case reports by Wei, Bo, Hang, Xiaofeng, Xie, Ying, Zhang, Yuanjing, Wang, Jianrong, Cao, Xinghao, Wu, Jinzi J, Wang, Junxue

“…Coronavirus disease (COVID-19), caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has been declared a pandemic. We herein report four…”
Get full text

Nanoparticles Targeted With NGR Motif Deliver c-myc siRNA and Doxorubicin for Anticancer Therapy by Chen, Yunching, Wu, Jinzi J, Huang, Leaf

“…We have designed a PEGylated LPD (liposome-polycation-DNA) nanoparticle for systemic, specific, and efficient delivery of small interfering RNA (siRNA) into…”
Get full text

First clinical study using HCV protease inhibitor danoprevir to treat COVID-19 patients by Chen, Hongyi, Zhang, Zhicheng, Wang, Li, Huang, Zhihua, Gong, Fanghua, Li, Xiaodong, Chen, Yahong, Wu, Jinzi J

“…As coronavirus disease 2019 (COVID-19) outbreak globally, repurposing approved drugs is emerging as important therapeutic options. Danoprevir boosted by…”
Get full text

Enhanced Antitumor Efficacy of Clinical-Grade Vasculature-Targeted Liposomal Doxorubicin by PASTORINO, Fabio, DI PAOLO, Daniela, MARIMPIETRI, Danilo, PAGNAN, Gabriella, CILLI, Michele, LEPEKHIN, Eugene A, GARDE, Seema V, LONGHI, Renato, CORTI, Angelo, ALLEN, Theresa M, WU, Jinzi J, PONZONI, Mirco, PICCARDI, Federica, NICO, Beatrice, RIBATTI, Domenico, DAGA, Antonio, BAIO, Gabriella, NEUMAIER, Carlo E, BRIGNOLE, Chiara, LOI, Monica

“…Purpose: In vivo evaluation of good manufacturing practice-grade targeted liposomal doxorubicin (TVT-DOX), bound to a CD13 isoform expressed on the vasculature…”
Get full text

A randomized phase 2b study of subcutaneous PD-L1 antibody ASC22 in virally-suppressed, HBeAg negative chronic hepatitis B patients by Qian, Jiandan, Xie, Yao, Mao, Qianguo, Xie, Qing, Gu, Ye, Chen, Xinyue, Hu, Guoxin, Yang, Yongfeng, Lu, Jiajie, Zou, Guizhou, Zhang, Qin, Fu, Lei, Chen, Yongping, Guo, Xiaolin, Hou, Jinlin, Yan, Yuemei, Wu, Jinzi J, Cui, Yimin, Wang, Guiqiang

“…Studies have shown that blocking the PD-1/PD-L1 pathway may lead to a potential cure for HBV infections. ASC22 (Envafolimab) is a humanized, single-domain…”
Get full text

A randomized phase 2b study of subcutaneous PD-L1 antibody ASC22 in virally suppressed patients with chronic hepatitis B who are HBeAg-negative by Qian, Jiandan, Xie, Yao, Mao, Qianguo, Xie, Qing, Gu, Ye, Chen, Xinyue, Hu, Guoxin, Yang, Yongfeng, Lu, Jiajie, Zou, Guizhou, Zhang, Qin, Fu, Lei, Chen, Yongping, Guo, Xiaolin, Hou, Jinlin, Yan, Yuemei, Wu, Jinzi J., Cui, Yimin, Wang, Guiqiang

“…Background and Aims: Studies have shown that blocking the programmed cell death-1/programmed cell death ligand 1 pathway may lead to a potential cure for HBV…”
Get full text

In Vitro Antiviral Activity and Cross-Resistance Profile of PL-100, a Novel Protease Inhibitor of Human Immunodeficiency Virus Type 1 by DANDACHE, Serge, SEVIGNY, Guy, YELLE, Jocelyn, STRANIX, Brent R, PARKIN, Neil, SCHAPIRO, Jonathan M, WAINBERG, Mark A, WU, Jinzi J

“…Classifications Services AAC Citing Articles Google Scholar PubMed Related Content Social Bookmarking CiteULike Delicious Digg Facebook Google+ Mendeley Reddit…”
Get full text

Twelve‐week ravidasvir plus ritonavir‐boosted danoprevir and ribavirin for non‐cirrhotic HCV genotype 1 patients: A phase 2 study by Kao, Jia‐Horng, Yu, Min‐Lung, Chen, Chi‐Yi, Peng, Cheng‐Yuan, Chen, Ming‐Yao, Tang, Huoling, Chen, Qiaoqiao, Wu, Jinzi J

“…Background and Aim The need for all‐oral hepatitis C virus (HCV) treatments with higher response rates, improved tolerability, and lower pill burden compared…”
Get full text

Protein tyrosine kinases: Structure, substrate specificity, and drug discovery by Al-Obeidi, Fahad A., Wu, Jinzi J., Lam, Kit S.

“…Protein tyrosine kinases (PTKs) play a crucial role in many cell regulatory processes. It is therefore not surprising to see that functional perturbation of…”
Get full text

Pyridoxine hydroxamic acids as novel HIV-integrase inhibitors by Stranix, Brent R., Wu, Jinzi J., Milot, Guy, Beaulieu, Françis, Bouchard, Jean-Emanuel, Gouveia, Kristine, Forte, André, Garde, Seema, Wang, Zhigang, Mouscadet, Jean-François, Delelis, Olivier, Xiao, Yong

“…A series of pyridoxine hydroxamic acid derivatives were prepared and evaluated as inhibitors of HIV integrase complex and wild type virus. [Display omitted] A…”
Get full text

Ritonavir-boosted danoprevir plus peginterferon alfa-2a and ribavirin in Asian chronic hepatitis C patients with or without cirrhosis by Kao, Jia-Horng, Tung, Shui-Yi, Lee, Younjae, Thongsawat, Satawat, Tanwandee, Tawesak, Sheen, I.-Shyan, Wu, Jinzi J., Li, Hui, Brennan, Barbara J., Zhou, Julian, Le Pogam, Sophie, Najera, Isabel, Thommes, James A., Hill, George

“…Background and Aim Chronic hepatitis C is an important public health problem in Asia. We evaluated the safety, efficacy, and pharmacokinetics of fixed‐dose…”
Get full text

Binding and internalization of NGR-peptide-targeted liposomal doxorubicin (TVT-DOX) in CD13-expressing cells and its antitumor effects by Garde, Seema V, Forté, André J, Ge, Michael, Lepekhin, Eugene A, Panchal, Chandra J, Rabbani, Shafaat A, Wu, Jinzi J

“…In an effort to develop new agents and molecular targets for the treatment of cancer, aspargine-glycine-arginine (NGR)-targeted liposomal doxorubicin (TVT-DOX)…”
Get full text

Antimicrobial drug discovery through bacteriophage genomics by Arhin, Francis, Ha, Nhuan, DuBow, Michael, McCarty, John, Moeck, Greg, Gros, Philippe, Callejo, Mario, Kwan, Tony, Liu, Jing, Srikumar, Ramakrishnan, Ferretti, Vincent, Dehbi, Mohammed, Wu, Jinzi J, Pelletier, Jerry, Bauda, Pascale, Bergeron, Dominique, Williams, Dan

“…Over evolutionary time bacteriophages have developed unique proteins that arrest critical cellular processes to commit bacterial host metabolism to phage…”
Get full text

Efficacy and Safety of All-oral, 12-week Ravidasvir Plus Ritonavir-boosted Danoprevir and Ribavirin in Treatment-naïve Noncirrhotic HCV Genotype 1 Patients: Results from a Phase 2/3 Clinical Trial in China by Xu, Xiaoyuan, Feng, Bo, Guan, Yujuan, Zheng, Sujun, Sheng, Jifang, Yang, Xingxiang, Ma, Yuanji, Huang, Yan, Kang, Yi, Wen, Xiaofeng, Li, Jun, Tan, Youwen, He, Qing, Xie, Qing, Wang, Maorong, An, Ping, Gong, Guozhong, Liu, Huimin, Ning, Qin, Hua, Rui, Ning, Bo, Xie, Wen, Zhang, Jiming, Huang, Wenxiang, Yang, Yongfeng, Lin, Minghua, Zhao, Yingren, Yu, Yanhong, Jia, Jidong, Yang, Dongliang, Chen, Liang, Ye, Yinong, Nan, Yuemin, Gong, Zuojiong, Zhang, Quan, Hu, Peng, Wang, Fusheng, Li, Yongguo, Li, Dongliang, Jia, Zhansheng, Hou, Jinlin, Chen, Chengwei, Wu, Jinzi J., Wei, Lai

“…Background and Aims: Ravidasvir (RDV) is a new generation pangenotypic hepatitis C virus (HCV) NS5A inhibitor, with high barrier to baseline…”
Get full text

Efficacy and Safety of 12-week Interferon-based Danoprevir Regimen in Patients with Genotype 1 Chronic Hepatitis C by Wei, Lai, Shang, Jia, Ma, Yuanji, Xu, Xiaoyuan, Huang, Yan, Guan, Yujuan, Duan, Zhongping, Zhang, Wenhong, Gao, Zhiliang, Zhang, Mingxiang, Li, Jun, Jia, Jidong, Yang, Yongfeng, Wen, Xiaofeng, Wang, Maorong, Jia, Zhansheng, Ning, Bo, Chen, Yongping, Qi, Yue, Du, Jie, Jiang, Jianning, Tong, Lixin, Xie, Yao, Wu, Jinzi J.

“…Background and Aims:Genotype (GT) 1 remains the predominant hepatitis c virus (HCV) GT in Chinese patients.Over 80％ of those Chinese patients harbor the…”
Get full text

Identification of a high-affinity anti-phosphoserine antibody for the development of a homogeneous fluorescence polarization assay of protein kinase C by Wu, J J, Yarwood, D R, Pham, Q, Sills, M A

“…In the last few years, fluorescence polarization (FP) has been applied to the development of robust, homogeneous, high throughput assays in molecular…”
Get more information

PL-100, a novel HIV-1 protease inhibitor displaying a high genetic barrier to resistance: An in vitro selection study by Dandache, Serge, Coburn, Craig A, Oliveira, Maureen, Allison, Timothy J, Holloway, M. Katharine, Wu, Jinzi J, Stranix, Brent R, Panchal, Chandra, Wainberg, Mark A, Vacca, Joseph P

“…The development of new HIV inhibitors with distinct resistance profiles is essential in order to combat the development of multi-resistant viral strains. A…”
Get full text

Comparison of assay technologies for a tyrosine kinase assay generates different results in high throughput screening by Sills, Matthew A, Weiss, Donna, Pham, Quynhchi, Schweitzer, Robert, Wu, Xiang, Wu, Jinzi J

“…In today's high-throughput screening (HTS) environment, an increasing number of assay detection technologies are routinely utilized in lead finding programs…”
Get more information

Contribution of the 37-kDa laminin receptor precursor in the anti-metastatic PSP94-derived peptide PCK3145 cell surface binding by Annabi, Borhane, Currie, Jean-Christophe, Bouzeghrane, Mounia, Dulude, Hélène, Daigneault, Luc, Garde, Seema, Rabbani, Shafaat A., Panchal, Chandra, Wu, Jinzi J., Béliveau, Richard

“…PCK3145 is an anti-metastatic synthetic peptide with promising therapeutic efficacy against hormone-refractory prostate cancer. The characterization of the…”
Get full text